How the New Administration will React on Recreational vs Medical
MIAMI, FL / ACCESSWIRE / November 29, 2016 / Novus Acquisition and Development, Corp. (OTC Markets: NDEV), is a diversified
insurance entity in health, liability and excess. Novus is the nation's first healthcare insurance carrier/aggregator in the
medical cannabis sector.
The day Donald Trump was elected president, four states legalized marijuana for recreational use, while four others legalized or
expanded access to medical marijuana. As a result of those ballot initiatives, most states now recognize marijuana as a medicine,
and one in five Americans live in a state that has decided to tolerate medical cannabis consumption with a doctor's note. Trump
campaigned on a platform of marijuana and legalization, stating; "I think that it should be a state issue, state-by-state," he said
to The Washington Post last year. He later told Bill O'Reilly that he is "100 percent" in support of medical marijuana.
So as an investor let's asses this situation; Trump is for medical marijuana and no particular stance on recreational, but for
the states that just legalized it then the Trump administration would have a monumental cost of fighting this cause state by state,
leaving less federal funds to fight the crimes that matter to the American public.
While a spending rider that is likely to be renewed protects medical marijuana suppliers from the feds, this rider was approved
by Congress in 2014 and 2015 prohibiting the Justice Department from prosecuting marijuana suppliers who "fully comply" with state
laws allowing medical use of the plant. A three-judge panel of the U.S. Court of Appeals for the 9th Circuit said federal marijuana
defendants are entitled to evidentiary hearings at which they can try to show their actions were authorized by state law. Therefore
if Sessions, if given free rein and he is in a marijuana destruction mode he could easily destroy in the recreational industry (not
without being challenged) but not the medical marijuana industry.
Sessions also could challenge state legalization in federal court. While the DOJ might prevail in arguing that state licensing
and regulation of cannabis businesses conflicts with federal law, it cannot force states to re-criminalize on existing businesses,
making sense?
There are only two Federal Departments that do not uphold against popular vote, they are the DEA and the FDA for obvious
reasons, but neither department has regulatory authority over appropriations of funds, Congress does. So, what we have here is most
Americans (60 percent, according to Gallup) think marijuana should be legal, while most Republicans continue to oppose legalization
federally, and that's ok with businesses in medial marijuana practices, such as Novus' business model. But even among Republicans,
most—70 percent, according to CBS News poll conducted last April—think the feds should not try to override state decisions in this
area. Again leaving cannabis in recreational realm open for discretion not medical marijuana and any challenges against either one
would be an up hill legal battle that can reign for years.
In summary:
- Collectively the estimated American voters for marijuana legalization was 160 million and total number of votes
Trump and Clinton combined was 124 million votes (chalk this up to the American voters) - If Sessions goes rough shot over this
issue it will take away from other crimes in America that are more prevalent, again, leaving recreational more venerable and
medical marijuana a much safer alternative - Trump abiding to his promise to respect state medical marijuana policies could please
left-leaning voters in the house and the DOJ.
All the president-elect has to do is leave this issue alone. And let both recreational and medical continue to gain market
share, which is estimated to be $50 billion by 2020, and tremendous job growth.
NDEV 3rd Quarter Financial Filing:
http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related
insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has positioned
itself to gain market share within many lines of insurance business within and outside of the MMJ sector.
Novus will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on
the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the
Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The
statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not
intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained
on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your
physician or other health care professional. Once a push notification is competed the transaction is solely between the
state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated
that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by
state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current
administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any
such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus
Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a
change in enforcement by federal or state governments.
- For more information, check out: http://www.getnovusnow.com - For NDEV
3rd Quarter Financial Filing: http://www.otcmarkets.com/financialReportViewer?symbol=NDEV&id=162770 - Learn How Insurance
Companies Are Evaluated: http://bit.ly/2ddIYva
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current
expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. Some of these factors include: general global economic conditions;
general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the
expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve
commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy;
changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not
anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Novus Medical Group disclaims
any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Contact Information
Corporate: Chairman and CEO Frank Labrozzi frank@ndev.biz 855-228-7355
Investors: Hayden IR hart@haydenir.com 917-658-7878
SOURCE: Novus Acquisition and Development, Corp.
